(Q30252234)

13 June 2017

title

ZP1609/Danegaptide and mitochondrial connexin hemichannels: a harbinger for peptide drug design (English)

1 reference

13 June 2017

2

Brant E Isakson

1 reference

13 June 2017

1

Leon J DeLalio

1 reference

13 June 2017

language of work or name

English

0 references

publication date

1 June 2017

1 reference

British Journal of Pharmacology

13 June 2017

published in

1 reference

The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43.

13 June 2017

volume

174

0 references

issue

15

0 references

page(s)

2606-2607

0 references

cites work

1 reference

Next-Generation Connexin and Pannexin Cell Biology

21 January 2018

1 reference

Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.

21 January 2018

1 reference

RETRACTED: Glycogen synthase kinase 3β transfers cytoprotective signaling through connexin 43 onto mitochondrial ATP-sensitive K+ channels.

21 January 2018

1 reference

Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection

21 January 2018

1 reference

The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs

21 January 2018

1 reference

Retraction for Rottlaender et al., "Glycogen synthase kinase 3β transfers cytoprotective signaling through connexin 43 onto mitochondrial ATP-sensitive K+ channels".

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513857

26 November 2018

Identifiers

DOI

10.1111/BPH.13891

1 reference

13 June 2017

0 references

1 reference